648 filings
8-K
VXRT
Vaxart Inc
14 Jun 24
Vaxart Announces $40 Million Underwritten Offering of Common Stock
6:03am
8-K
VXRT
Vaxart Inc
13 Jun 24
Entry into a Material Definitive Agreement
5:26pm
8-K
VXRT
Vaxart Inc
13 Jun 24
Departure of Directors or Certain Officers
4:07pm
10-Q
2024 Q1
VXRT
Vaxart Inc
Quarterly report
13 May 24
4:11pm
8-K
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
8-K
e208566v6 p8qhxy
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
ARS
hof5s
29 Apr 24
Annual report to shareholders
4:39pm
DEFA14A
dx0 2gc241ofq6b
29 Apr 24
Additional proxy soliciting materials
4:38pm
S-8
rr3 x0nrmp7
14 Mar 24
Registration of securities for employees
4:56pm
8-K
bv0hayi6xqf kv003k5
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
zfyg56
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
hm64kecy l2w
29 Feb 24
Departure of Directors or Certain Officers
4:30pm
8-K
s02 ouc43fin4hnpy3e
15 Feb 24
Other Events
4:10pm
8-K/A
lowc5ta
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K
6q7kd67e3s6chy4y6
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
jab xtd4x9w
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
bfpexd py52je2fj
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm